Can gabapentin (Neurontin) help alleviate anxiety symptoms?

Gabapentin for Anxiety: Limited Evidence and Not First-Line

Gabapentin (Neurontin) is NOT recommended as a first-line treatment for anxiety disorders and should only be considered as a second-line option in specific contexts, particularly for social anxiety disorder, after SSRIs/SNRIs have failed or are not tolerated. The FDA has not approved gabapentin for any anxiety disorder, and anxiety is not an indication in the drug label 1.

Guideline Recommendations

The most recent and authoritative guideline evidence comes from the 2023 Japanese Society of Anxiety and Related Disorders, which specifically addresses gabapentin's role:

• For social anxiety disorder: The Canadian Clinical Practice Guideline lists gabapentin as a second-line agent only, after first-line SSRIs (escitalopram, fluvoxamine, paroxetine, sertraline), SNRI (venlafaxine), and pregabalin 2
• First-line treatments remain: SSRIs and SNRIs are the standard pharmacotherapy across all major guidelines (NICE, S3, Canadian CPG) 2
• Notably, pregabalin (gabapentin's more studied cousin) is listed as first-line in Canadian guidelines, but gabapentin itself is relegated to second-line status 2

Critical Safety Concerns from FDA Label

The Neurontin FDA label contains important warnings that directly impact anxiety treatment:

• May increase risk of suicidal thoughts and behavior - patients must be monitored for emergence or worsening of depression, unusual mood changes, or suicidal ideation 1
• Causes CNS depression including dizziness and somnolence 1
• Post-marketing reports specifically document anxiety as an adverse event following abrupt discontinuation, along with insomnia, nausea, pain, and sweating 1

This creates a problematic paradox: using gabapentin to treat anxiety when withdrawal from the medication can cause rebound anxiety.

Research Evidence: Mixed and Inconclusive

Generalized Anxiety Disorder (GAD)

• No randomized controlled trials exist for GAD - only case reports 3, 4
• One 2017 case report showed dose-response pattern in a single patient, but this is insufficient evidence 3
• A 2015 systematic review concluded: "There is no clear evidence for gabapentin therapy in...generalized anxiety disorder" 4

Panic Disorder

• A 2000 placebo-controlled trial (n=103) found no overall drug/placebo difference (p=0.606) 5
• Post-hoc analysis suggested possible benefit only in severely ill patients (PAS score ≥20), but this was not the primary outcome 5

Social Anxiety Disorder

• The 2023 guideline notes "few studies of pharmacotherapy for inadequate response or intolerance to SSRIs and SNRIs, and RCTs for classes of drugs other than SSRIs and SNRIs are lacking" 2

Situational/Preoperative Anxiety

• Studies show gabapentin 1200 mg reduces preoperative anxiety effectively 6, 7
• However, this is situational anxiety, not chronic anxiety disorders
• Significant sedation occurs (Effect size -3.02), which may delay discharge 6

Breast Cancer Survivors

• One 2012 RCT (n=420) showed gabapentin 300-900 mg improved anxiety at 4 and 8 weeks 8
• Effect was proportional to baseline anxiety severity
• Lower dose (300 mg) performed better except in highest anxiety patients 8

Critical Concerns About Long-Term Use

A 2021 review raises serious red flags about gabapentinoids for mental health conditions 9:

• Tolerance, dependence, addiction, and withdrawal issues similar to benzodiazepines
• 244 deaths involving pregabalin recorded in 2019 in England alone
• Death rates from pregabalin now exceed those from diazepam, fentanyl, tricyclics, or SSRIs
• Evidence for anxiety comes only from short-term trials with marginal placebo differences
• Authors call for re-evaluation of gabapentinoid use in psychiatric conditions 9

Clinical Algorithm

If considering gabapentin for anxiety:

1. First, ensure adequate trials of first-line agents:

   • SSRIs: escitalopram, sertraline, paroxetine, fluvoxamine
   • SNRI: venlafaxine
   • Consider pregabalin before gabapentin (better evidence, first-line in some guidelines)

2. If first-line agents fail or are contraindicated:

   • For social anxiety disorder specifically: gabapentin may be considered as second-line 2
   • For GAD, panic disorder, or other anxiety disorders: insufficient evidence to recommend

3. If prescribing gabapentin:

   • Start 300 mg daily (lower doses performed better in breast cancer study) 8
   • Monitor closely for suicidal ideation and mood changes 1
   • Warn about sedation and CNS depression 1
   • Plan for time-limited trial, not indefinite use 9
   • Taper slowly if discontinuing to avoid rebound anxiety 1

4. Avoid in:

   • Patients with substance use history (addiction potential)
   • Patients requiring alertness for work/driving (sedation)
   • First-line treatment of any anxiety disorder

Common Pitfalls

• Off-label use without evidence: Gabapentin is widely prescribed for anxiety despite lack of FDA approval and limited trial data 4
• Ignoring withdrawal risks: Abrupt discontinuation causes anxiety, creating a vicious cycle 1
• Overlooking mortality data: The rising death rates associated with gabapentinoids deserve serious consideration 9
• Bypassing proven treatments: SSRIs/SNRIs have robust evidence and should be exhausted first 2